Oncology Clinical Trials/Research

E-mail Print PDF

The Research Institute at St. Joseph's Regional Medical Center strives to improve our patient's quality of life, advance science, and develop better standards of care.

If you have been diagnosed with cancer, we invite you to call us at the Office of Clinical Trials. Our treatment protocols are sponsored by the National Cancer Institute and other large cooperative cancer groups in the United States. These programs may be beneficial to you since they provide excellent comprehensive cancer care, as well as long term monitoring and follow-up. In general, participation in a trial does not increase the cost of your medical care. In most cases, the study drugs and some of required tests are provided to you free of charge.


If you enroll in a study, you do not have to change your oncologist. Our office works along with your private or clinic oncologist to coordinate your care. Your doctor will remain with you during all of your treatment. Your participation is very important. Clinical trials help us to learn more about cancer and to discover new and more effective ways of treating cancer.


Please call us for further information. We would be happy to speak with you and answer any of your questions concerning our clinical trials.


If you are interested in participating in an Oncology Study, please contact:

Maria Delia Lucila, RN BSN CCRP Clinical Research Nurse at 973.754.2405 or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it .


For all other research related inquiries, please contact:

Lindsey Meade, Manager of Research, at 973.754.2416 or email This e-mail address is being protected from spambots. You need JavaScript enabled to view it .



The Oncology Research Institute at St. Joseph's Regional Medical Center is currently enrolling patients in the following studies:

Principal Investigator: Michael Maroules, MD

Sub – Investigator : Motria Ukrainskyj, MD


SWOG S1007; PR# 12-002 "A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less."


ECOG- E3108 : PR # 11-032 "A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen ."


NSABP PROTOCOL B-47 : PR # 11-033 "A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer"


NSABP-B43; PR# 11-050 "A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy."


CALGB 50303; PR# 06-019 "Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas


For more information contact Maria Delia Lucila, RN BSN CCRP, Clinical Research Nurse, Clinical Trials Office at  This e-mail address is being protected from spambots. You need JavaScript enabled to view it or 973.754.2405


100 great places logo

web-Magnet CMYK

Magnet Text

usnews besthospitals 2013.14


mw winner2013


teaching bg

buy cialis online

buy viagra online

buy propecia online